Compositions and methods for ameliorating Helicobacteraceae infections
AssigneeUniversity of Oregon
InventorArden Baylink
Life of this patent
Estimating the term…
Abstract
A pharmaceutical composition includes a Helicobacteraceae enzyme inhibitor and a pharmaceutically acceptable carrier. The enzyme inhibitor may inhibit peroxiredoxin, such as alkyl hydroperoxide reductase C, thiol-specific peroxidase, bacterioferritin comigratory protein, or any combination thereof. A method for ameliorating a Helicobacteraceae infection includes administering to a subject a therapeutically effective amount of a pharmaceutical composition including a Helicobacteraceae enzyme inhibitor and a pharmaceutically acceptable carrier.
Claims16
An oral dosage form comprising an immediate release coating or capsule shell formulated to dissolve in a subject's stomach and/or duodenum, wherein the immediate release coating or capsule shell encapsulates a Helicobacteraceae enzyme inhibitor and a pharmaceutically acceptable carrier, and
- wherein the Helicobacteraceae enzyme inhibitor is selected from
- (i)
- (ii) a compound having a structure according to Formula I′, II′, III′, V′, or VI′;
- (iii) a stereoisomer, pharmaceutically acceptable salt, solvate, or hydrate of (i) or (ii);
- or
- (iv) any combination of two or more of (i)-(iii),
- wherein Formulas I′, II′, III′, V′, and VI′ are
A method for ameliorating Helicobacter pylori infection, comprising administering a therapeutically effective amount of an oral dosage form to a subject having, or suspected of having, Helicobacter pylori infection,
- wherein the oral dosage form comprises an immediate release coating or capsule shell formulated to dissolve in the subject's stomach and/or duodenum, wherein the immediate release coating or capsule shell encapsulates a Helicobacteraceae enzyme inhibitor and a pharmaceutically acceptable carrier, and
- wherein the Helicobacteraceae enzyme inhibitor is selected from
- (i)
- (ii) a compound having a structure according to Formula I′, II′, III′, V′, or VI′;
- (iii) a stereoisomer, pharmaceutically acceptable salt, solvate, or hydrate of (i) or (ii);
- or
- (iv) any combination of two or more of (i)-(iii),
- wherein Formulas I′, II′, III′, V′, and VI′ are
A method, comprising inhibiting an enzyme produced by Helicobacter pylori by contacting the enzyme with an effective amount of an oral dosage form comprising an immediate release coating or capsule shell formulated to dissolve in a subject's stomach and/or duodenum, wherein the immediate release coating or capsule shell encapsulates a Helicobacteraceae enzyme inhibitor and a pharmaceutically acceptable carrier, and
- wherein the Helicobacteraceae enzyme inhibitor is selected from
- (i)
- (ii) a compound having a structure according to Formula I′, II′, III′, V′, or VI′;
- (iii) a stereoisomer, pharmaceutically acceptable salt, solvate, or hydrate of (i) or (ii);
- or
- (iv) any combination of two or more of (i)-(iii),
- wherein Formulas I′, II′, III′, V′, and VI′ are
- wherein each X independently is halo, and R1-R7 independently are H or C1-C5 alkyl.
Dependencies are inferred from the claim text.